Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

Bibliographic Details
Main Authors: Marie Luise Hütter-Krönke, Walter Fiedler, Andrea Kündgen, Jürgen Krauter, Marie von Lilienfeld-Toal, Hartmut Döhner, Richard F. Schlenk
Format: Article
Language:English
Published: Ferrata Storti Foundation 2019-02-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/8788

Internet

https://haematologica.org/article/view/8788

Similar Items